In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection

Qun Yan; Melissa J. Karau; Robin Patel

doi:10.1016/j.diagmicrobio.2018.05.010

In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection

Qun Yan, Melissa J. Karau, Robin Patel

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC₅₀ for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC₉₀ for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups. The oritavancin MBBC₅₀ for S. aureus and S. epidermidis was 2 μg/mL for both the methicillin-resistant and -susceptible subgroups; the MBBC₉₀ for S. aureus and MSSE was 4 μg/mL, and for MRSE, it was 8 μg/mL.

Original language	English (US)
Pages (from-to)	155-157
Number of pages	3
Journal	Diagnostic Microbiology and Infectious Disease
Volume	92
Issue number	2
DOIs	https://doi.org/10.1016/j.diagmicrobio.2018.05.010
State	Published - Oct 2018

Keywords

Biofilm
Oritavancin
Prosthetic joint infection
Staphylococci

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2018.05.010

Cite this

@article{d2082ce028d24d57b5443da0934b5c46,

title = "In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection",

abstract = "We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC50 for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC90 for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups. The oritavancin MBBC50 for S. aureus and S. epidermidis was 2 μg/mL for both the methicillin-resistant and -susceptible subgroups; the MBBC90 for S. aureus and MSSE was 4 μg/mL, and for MRSE, it was 8 μg/mL.",

keywords = "Biofilm, Oritavancin, Prosthetic joint infection, Staphylococci",

author = "Qun Yan and Karau, {Melissa J.} and Robin Patel",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = oct,

doi = "10.1016/j.diagmicrobio.2018.05.010",

language = "English (US)",

volume = "92",

pages = "155--157",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection

AU - Yan, Qun

AU - Karau, Melissa J.

AU - Patel, Robin

PY - 2018/10

Y1 - 2018/10

N2 - We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC50 for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC90 for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups. The oritavancin MBBC50 for S. aureus and S. epidermidis was 2 μg/mL for both the methicillin-resistant and -susceptible subgroups; the MBBC90 for S. aureus and MSSE was 4 μg/mL, and for MRSE, it was 8 μg/mL.

AB - We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC50 for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC90 for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups. The oritavancin MBBC50 for S. aureus and S. epidermidis was 2 μg/mL for both the methicillin-resistant and -susceptible subgroups; the MBBC90 for S. aureus and MSSE was 4 μg/mL, and for MRSE, it was 8 μg/mL.

KW - Biofilm

KW - Oritavancin

KW - Prosthetic joint infection

KW - Staphylococci

UR - http://www.scopus.com/inward/record.url?scp=85048496818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048496818&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2018.05.010

DO - 10.1016/j.diagmicrobio.2018.05.010

M3 - Article

C2 - 29885758

AN - SCOPUS:85048496818

SN - 0732-8893

VL - 92

SP - 155

EP - 157

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 2

ER -

In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this